ANP32A peptide

GeneTex

ANP32A peptide

9

The peptide is used for blocking the activity of PHAP I antibody (cat. no GTX25992). It usually blocks the antibody activity completely in Western blot by incubating the peptide with equal volume of antibody for 30 min at 37C.

Neutralisation/Blocking

Research Use Only

0.20 mg/ml

Unconjugated

ANP32A

acidic nuclear phosphoprotein 32 family member A

C15orf1, HPPCn, I1PP2A, LANP, MAPM, PHAP1, PHAPI, PP32, acidic leucine-rich nuclear phosphoprotein 32 family member A, acidic (leucine-rich) nuclear phosphoprotein 32 family, member A, acidic nuclear phosphoprotein pp32, cerebellar leucine rich acidic nuclear protein, epididymis secretory sperm binding protein, hepatopoietin Cn, inhibitor-1 of protein phosphatase-2A, leucine-rich acidic nuclear protein, mapmodulin, potent heat-stable protein phosphatase 2A inhibitor I1PP2A, putative HLA-DR-associated protein I, putative human HLA class II associated protein I

Apoptosis is related to many diseases and development. Caspase-9 plays a central role in cell death induced by a variety of apoptosis activators. Cytochrome c, after release from mitochondria, binds to Apaf-1, which forms an apoptosome that in turn binds to and activates procaspase-9. Activated caspase-9 cleaves and activates the effector caspases (caspase-3, -6 and -7), which are responsible for the proteolytic cleavage of many key proteins in apoptosis. The tumor suppressor putative HLA-DR-associated proteins (PHAPs) were recently identified as important regulators of mitochondrion apoptosis. PHAP appears to facilitate apoptosome-mediated caspase-9 activation and to stimulate the mitochondrial apoptotic pathway. PHAP was also shown to oppose both Ras- and Myc-mediated cell transformation.

-20°C

41116100

Human